Navigation Links
Access Pharmaceuticals Presents New Data at International Symposium Showing Company's Angiolix(R) Monoclonal Antibody has Potential to Treat Cancer by Attacking Cancer Stem Cells
Date:6/26/2008

DALLAS, June 26 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that the Company gave an oral presentation yesterday on its monoclonal antibody product, Angiolix(R), at the 7th International Congress on Recombinant Antibodies, held in Dublin, Ireland. Dr. Agamemnon Epenetos, Access' Chief Scientific Officer -- Europe, presented data showing that Angiolix has the potential to prevent the growth of cancer stem cells.

Dr. Epenetos commented, "There is a growing body of evidence that indicates that tumor progression, dissemination and metastases result from cancer stem cells rather than the other cells which form the bulk of a cancer. As a result, therapies which attack these tumor cells will delay the onset of progression, but rarely cure the disease. Cancer stem cells are a subgroup of cancer cells that can be resistant to standard treatments, so agents like Angiolix, which have the potential to thwart cancer stem cells, hold great promise for the future treatment and eradication of cancer."

Access' monoclonal antibody product, Angiolix, blocks angiogenesis by inhibiting a novel receptor called lactadherin. Lactadherin causes angiogenesis through a VEGF dependent mechanism. Several other drugs have been developed or are in development to block VEGF and VEGF induced angiogenesis, such as Avastin.

In the presentation, Dr. Epenetos showed that Angiolix has been shown not only to block new blood vessels in tumors, in a similar manner to other anti VEGF drugs like Avastin, but that it could additionally have a direct killing effect on tumor cells potentially including cancer stem cells that are involved in angiogenesis and metastasis.

Access Pharmaceuticals is currently conducting key preclinical studies at Imperial College London, UK to assess the efficacy of Angiolix in a wide range of tumor models. These studies aim to demonstrate the potential efficacy of Angiolix as a monotherapy and in com
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
2. A Perfect Storm Threatens Patient Access to Specialty Medical Care
3. AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response
4. Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
5. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
6. AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy
7. Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. SurgiQuest Announces First Single Port Procedure for Ovary Removal Using AirSeal(TM) Access System
9. Scientists call for more access to biotech crop data
10. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
11. Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Pacific Biomarkers and Clinigene International are set to unveil ... the 2013 AAPS/ National Biotechnology Conference May ... Marina , San Diego, CA. ... with company representatives at their collaborative seminar, "Biosimilarity, Immunogenicity ... from 1-2 p.m. in the conference,s Spinnaker Room. ...
(Date:5/20/2013)... BALTIMORE , May 20, 2013   ... partnership focusing on commercializing market-relevant biohealth innovations and ... Central Maryland , today announced its selection ... Entrepreneur-in-Residence (EIR) for BHI at the National Institutes ... Blood Institute (NHLBI). Dr. Aiyar will help ...
(Date:5/20/2013)...   Flexion Therapeutics , Inc. today announced the ... to its management team as chief financial officer. Mr. ... experience with biotechnology and medical device companies. ... officer for Novavax (NASDAQ: NVAX ) where ... million through a combination of investment funding and commercial ...
(Date:5/20/2013)... 2013 Interventional cardiologist Tony Farah, MD, ... (AGH) Cardiovascular Institute have helped pioneer many breakthroughs ... (CAD) over the past three decades, from new ... and coronary artery stent implantation. , Today, AGH officials ... prominent role in the study of a novel, first-of-its ...
Breaking Biology Technology:Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 2BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 3BioHealth Innovation, Inc. Names Ram Aiyar as Entrepreneur-in-Residence to NIH National Heart, Lung and Blood Institute 4Flexion Therapeutics Names Frederick Driscoll Chief Financial Officer 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4
... of how business is conducted today, how important is ... ,Important enough that the expectations bar has been raised ... in recent years with the number of costly or ... in importance. But IT failures are just the tip ...
... the seventh in a series of articles on developing start-up ... article focused on business taxes. , , ... are ready to begin hiring workers. As discussed in the ... taxes, Social Security and Medicare taxes, ...
... . - Third Wave Technologies of Madison has ... lawsuit brought against it by Digene Corp . , ... for the Western District of Wisconsin in Madison, where ... includes counterclaims against Digene, alleging that it has abused its ...
Cached Biology Technology:Fusion 2007: CEOs say bar is raised for CIOs 2Fusion 2007: CEOs say bar is raised for CIOs 3Fusion 2007: CEOs say bar is raised for CIOs 4Early Stage 7, Part I: Just what is an employee? 2Early Stage 7, Part I: Just what is an employee? 3Early Stage 7, Part I: Just what is an employee? 4Early Stage 7, Part I: Just what is an employee? 5
(Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
(Date:5/21/2013)... pharmacies and health stores, phosphatidylserine is a natural ... Proven to improve cognition and slow memory loss, ... memory impairment. Now a team headed by Prof. ... Aviv University,s Department of Human Molecular Genetics ... the functioning of genes involved in degenerative brain ...
(Date:5/21/2013)... University of Illinois at Chicago College of Medicine will study ... -- its main energy source -- and how changes in ... new $2 million, 4-year grant from the National Heart, Lung ... it uses fuel for energy. These changes may play a ... different in men and women, says E. Douglas Lewandowski, director ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Common food supplement fights degenerative brain disorders 2Do men's and women's hearts burn fuel differently? 2
... this time of global change, understanding the basics ... as important as predicting and planning for widespread ... animal behaviorsuch as plant toxin detection in bushbaby ... of native lizards to red imported fire ant ...
... WI, August 2nd, 2010 Scientists demonstrate that biochar, ... capture and store carbon, can reduce emissions of nitrous ... from agriculture settings. The finding will help develop strategies ... reduce agriculture,s influence on climate change. A research ...
... Bioengineers at the University of Pennsylvania have created ... substrate surfaces on which cells are grown without ... more controlled lab experiments on cellular mechanobiology, an ... how cells sense and respond to mechanical forces ...
Cached Biology News:Ecological scientists assess the fundamentals of animal behavior 2Ecological scientists assess the fundamentals of animal behavior 3Ecological scientists assess the fundamentals of animal behavior 4Is biochar the answer for ag? 2Mechanical regulation of cell substrates effects stem cell development, adhesion 2
Recombinant Mouse sTNF RII/TNFRSF1B...
Mouse Wnt-11 Affinity Purified Polyclonal Ab...
PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Biology Products: